FDA Approves Supernus’ ADHD Drug for Adults

The FDA has approved an expanded indication for Supernus Pharmaceuticals’ attention deficit hyperactivity disorder (ADHD) drug Qelbree (viloxazine) for adult patients with ADHD.

The nonstimulant drug was previously approved in April 2021 for pediatric patients between the ages of six and 17 years old.

The expanded approval was supported by positive results from a late-stage study in which the drug showed statistically significant improvements in treated patients compared to those who received a placebo.